Pluri INC 10-Q quarterly reports

Pluri Inc. reported a decrease in revenues for the nine and three months ended March 31, 2026, alongside an increase in R&D and G&A expenses, while highlighting ongoing liquidity concerns.

Pluri Inc. reported increased net losses and negative cash flow, raising substantial doubt about its going concern ability, while also receiving a Nasdaq non-compliance notice.

Pluri Inc. reported increased net losses and a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern, while pursuing diverse biotech ventures.

Pluri Inc.'s Q3 2025 shows revenue growth driven by CDMO and agtech sectors, but the company still grapples with net losses and reliance on external funding.

Pluri Inc. reports increased revenue for the six months ended December 31, 2024, driven by new business verticals, while continuing cost reduction and efficiency plans to manage operating losses.

Pluri Inc. saw a significant increase in revenue driven by its CDMO and agtech businesses, but also experienced a widening net loss in the first quarter of fiscal year 2025.

Pluri Inc. announced its Q3 2024 financial results, showcasing a decrease in net loss and the launch of new business divisions in CDMO and agtech, alongside a new patent approval.

Pluri Inc. saw increased revenue and reduced expenses in the second quarter of fiscal year 2024, while navigating ongoing operational and financial challenges.